These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 25900064)

  • 21. Potent antidiabetic effects of rivoglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, in obese diabetic rodent models.
    Kanda S; Nakashima R; Takahashi K; Tanaka J; Ogawa J; Ogata T; Yachi M; Araki K; Ohsumi J
    J Pharmacol Sci; 2009 Oct; 111(2):155-66. PubMed ID: 19809220
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
    Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
    Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Integrated fragment-based drug design and virtual screening techniques for exploring the antidiabetic potential of thiazolidine-2,4-diones: Design, synthesis and in vivo studies.
    Gupta S; Baweja GS; Singh S; Irani M; Singh R; Asati V
    Eur J Med Chem; 2023 Dec; 261():115826. PubMed ID: 37793328
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, synthesis, and structure-activity relationship studies of novel 2,4,6-trisubstituted-5-pyrimidinecarboxylic acids as peroxisome proliferator-activated receptor gamma (PPARgamma) partial agonists with comparable antidiabetic efficacy to rosiglitazone.
    Seto S; Okada K; Kiyota K; Isogai S; Iwago M; Shinozaki T; Kitamura Y; Kohno Y; Murakami K
    J Med Chem; 2010 Jul; 53(13):5012-24. PubMed ID: 20527969
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis, biological evaluation and molecular modeling studies of arylidene-thiazolidinediones with potential hypoglycemic and hypolipidemic activities.
    da Costa Leite LF; Veras Mourão RH; de Lima Mdo C; Galdino SL; Hernandes MZ; de Assis Rocha Neves F; Vidal S; Barbe J; da Rocha Pitta I
    Eur J Med Chem; 2007 Oct; 42(10):1263-71. PubMed ID: 17448573
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel Piperine Derivatives with Antidiabetic Effect as PPAR-γ Agonists.
    Kharbanda C; Alam MS; Hamid H; Javed K; Bano S; Ali Y; Dhulap A; Alam P; Pasha MA
    Chem Biol Drug Des; 2016 Sep; 88(3):354-62. PubMed ID: 27037532
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, synthesis and in-vivo hypoglycemic evaluation of novel non - TZD'S in a type - 2 diabetic model.
    Jadhav R; Gupta-Rajoria R; Pal T; Subramanian RC
    Med Chem; 2013 Feb; 9(1):104-11. PubMed ID: 22762162
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-inflammatory effect of antidiabetic thiazolidinediones prevents bone resorption rather than cartilage changes in experimental polyarthritis.
    Koufany M; Moulin D; Bianchi A; Muresan M; Sebillaud S; Netter P; Weryha G; Jouzeau JY
    Arthritis Res Ther; 2008; 10(1):R6. PubMed ID: 18199331
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Design, synthesis, and PPARalpha/gamma agonistic activity of novel tetrahydroisoquinoline derivatives].
    Yu R; Zhou YL; Huan Y; Liu Q; Shen ZF; Liu ZZ
    Yao Xue Xue Bao; 2011 Mar; 46(3):311-6. PubMed ID: 21626786
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design, synthesis, and biological evaluation of novel thiazolidinediones as PPARγ/FFAR1 dual agonists.
    Darwish KM; Salama I; Mostafa S; Gomaa MS; Helal MA
    Eur J Med Chem; 2016 Feb; 109():157-72. PubMed ID: 26774923
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of a novel selective PPARγ ligand with partial agonist binding properties by integrated in silico/in vitro work flow.
    Kouskoumvekaki I; Petersen RK; Fratev F; Taboureau O; Nielsen TE; Oprea TI; Sonne SB; Flindt EN; Jónsdóttir SÓ; Kristiansen K
    J Chem Inf Model; 2013 Apr; 53(4):923-37. PubMed ID: 23432662
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis, biological evaluation and molecular docking studies of novel 3,5-disubstituted 2,4-thiazolidinediones derivatives.
    Ranjan Srivastava A; Bhatia R; Chawla P
    Bioorg Chem; 2019 Aug; 89():102993. PubMed ID: 31129500
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.
    Kim MK; Chae YN; Kim HS; Choi SH; Son MH; Kim SH; Kim JK; Moon HS; Park SK; Shin YA; Kim JG; Lee CH; Lim JI; Shin CY
    Arch Pharm Res; 2009 May; 32(5):721-7. PubMed ID: 19471887
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antidiabetic and adipogenic properties in a newly synthesized thiazolidine derivative, FPFS-410.
    Norisada N; Masuzaki H; Fujimoto M; Inoue G; Hosoda K; Hayashi T; Watanabe M; Muraoka S; Yoneda F; Nakao K
    Metabolism; 2004 Dec; 53(12):1532-7. PubMed ID: 15562395
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacological characteristics of a novel nonthiazolidinedione insulin sensitizer, FK614.
    Minoura H; Takeshita S; Ita M; Hirosumi J; Mabuchi M; Kawamura I; Nakajima S; Nakayama O; Kayakiri H; Oku T; Ohkubo-Suzuki A; Fukagawa M; Kojo H; Hanioka K; Yamasaki N; Imoto T; Kobayashi Y; Mutoh S
    Eur J Pharmacol; 2004 Jun; 494(2-3):273-81. PubMed ID: 15212984
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis and biological activity of [[(heterocycloamino)alkoxy] benzyl]-2,4-thiazolidinediones as PPARgamma agonists.
    Jeon R; Kim YJ; Cheon Y; Ryu JH
    Arch Pharm Res; 2006 May; 29(5):394-9. PubMed ID: 16756084
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design and synthesis of a novel class of dual PPARgamma/delta agonists.
    Gonzalez IC; Lamar J; Iradier F; Xu Y; Winneroski LL; York J; Yumibe N; Zink R; Montrose-Rafizadeh C; Etgen GJ; Broderick CL; Oldham BA; Mantlo N
    Bioorg Med Chem Lett; 2007 Feb; 17(4):1052-5. PubMed ID: 17129725
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of new dual PPARγ-GPR40 agonists with robust antidiabetic activity: Design, synthesis and in combo drug evaluation.
    Hidalgo-Figueroa S; Navarrete-Vázquez G; Estrada-Soto S; Giles-Rivas D; Alarcón-Aguilar FJ; León-Rivera I; Giacoman-Martínez A; Miranda Pérez E; Almanza-Pérez JC
    Biomed Pharmacother; 2017 Jun; 90():53-61. PubMed ID: 28342366
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis and antihyperglycemic activity profiles of novel thiazolidinedione derivatives.
    Bhat BA; Ponnala S; Sahu DP; Tiwari P; Tripathi BK; Srivastava AK
    Bioorg Med Chem; 2004 Nov; 12(22):5857-64. PubMed ID: 15498661
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A new class of non-thiazolidinedione, non-carboxylic-acid-based highly selective peroxisome proliferator-activated receptor (PPAR) γ agonists: design and synthesis of benzylpyrazole acylsulfonamides.
    Rikimaru K; Wakabayashi T; Abe H; Imoto H; Maekawa T; Ujikawa O; Murase K; Matsuo T; Matsumoto M; Nomura C; Tsuge H; Arimura N; Kawakami K; Sakamoto J; Funami M; Mol CD; Snell GP; Bragstad KA; Sang BC; Dougan DR; Tanaka T; Katayama N; Horiguchi Y; Momose Y
    Bioorg Med Chem; 2012 Jan; 20(2):714-33. PubMed ID: 22209730
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.